Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | PRKCI | P41743 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 3/20 | 0.38 |
| ▸ | AXL | P30530 | 2/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TAF1 | P21675 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9942590 | 0.76 | AHR (0.43) | GRM5PRKCIAHRAXLNUDT1 | |
| SCHEMBL23233865 | 0.76 | GRM5 (0.41) | GRM5PRKCIAHRAXLNUDT1 | |
| SCHEMBL30122523 | 0.74 | DYRK1A (0.48) | GRM5PRKCIAHRAXLNUDT1 | |
| SCHEMBL30678614 | 0.74 | GRM5 (0.43) | GRM5PRKCIAHRAXLNUDT1 | |
| SCHEMBL30781502 | 0.74 | TNF (0.44) | GRM5PRKCIAHRAXLNUDT1 | |
| SCHEMBL1154874 | 0.74 | GRM5 (0.43) | GRM5PRKCIAHRAXLNUDT1 | |
| SCHEMBL2633337 | 0.74 | GRM5 (0.43) | GRM5AHRAXLNUDT1TNF | |
| SCHEMBL401223 | 0.74 | NOS3 (0.42) | GRM5PRKCIAHRAXLNUDT1 | |
| SCHEMBL762091 | 0.74 | DYRK1A (0.48) | GRM5PRKCIAHRAXLNUDT1 | |
| SCHEMBL18237616 | 0.71 | GRM5 (0.38) | GRM5PRKCIAHRAXLNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680423-A1 | AZABENZODIAZEPINES AS PHOSPHODIESTERASE-4 INHIBITORS | Warner-Lambert Company LLC (US) | 2006-07-19 | — | — | EP | claimed |
| WO-2005040168-A1 | AZABENZODIAZEPINES AS PHOSPHODIESTERASE-4 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-06 | — | — | WO | claimed |
| EP-1526135-A1 | Azabenzodiazepines as pde4 inhibitors | Warner-Lambert Company LLC (US) | 2005-04-27 | — | — | EP | claimed |
| CN-119330941-A | Antitumor compounds as UPR agonists and uses thereof | 南京圣和药业股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20240245675-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. | 2024-07-25 | — | — | US | disclosed |
| EP-4377298-A1 | PROTEIN SECRETION INHIBITORS | Gate Bioscience, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-117999256-A | Protein secretion inhibitor | 分子门生物科技公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023010051-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023010051-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
| CN-112105357-A | Pharmaceutically acceptable 6,5 heterobicyclic derivatives | UCB生物制药有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1363705-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-0673937-B1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | EISAI CO LTD (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207910-A1 | Treatment of HIV and AIDS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| US-20030069266-A1 | Aids therapy | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| WO-2002062423-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
| US-5721246-A | ANTITUMOR AGENTS; LOW TOXICITY | EISAI CO., LTD. (JP) | 1998-02-24 | — | — | US | disclosed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | STING1, IRF3, NFATC1 | GRM5 2193/4885PRKCI 675/4885AHR 2753/4885 |
| US-20030069266-A1 | Aids therapy | ENTPD5, CCR5, ITPA | GRM5 1443/4885PRKCI 3395/4885AHR 1309/4885 |
| US-20240245675-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | GRM5 3882/4885PRKCI 1057/4885AHR 4407/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | GRM5 1929/4885PRKCI 4545/4885AHR 2122/4885 |
| US-20030207910-A1 | Treatment of HIV and AIDS | CD4, CCR5, IDO1 | GRM5 1534/4885PRKCI 2931/4885AHR 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.